The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product dabrafenib (Tafinlar), 50 and 75 mg capsules, hard, intended for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Read more
here.
No comments:
Post a Comment